A Pilot Study to Evaluate the Effect of Eltrombopag Plus G-CSF on Human CD34+ Cell Mobilization and Ex Vivo Colony Proliferative Capacity in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation
Subjects will receive standard treatment for autologous stem cell transplant. Subjects will
be assigned to receive no Eltrombopag or one of three dose levels of Eltrombopag. Subjects
will receive oral Eltrombopag on days 2-15 of treatment.
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Supportive Care
Evaluate the median fold increase in the number of CD34+ cells/kg mobilized at each dose level.
Nancy Berliner, MD
Dana-Farber Cancer Institute
United States: Food and Drug Administration
|Dana Farber Cancer Institute||Boston, Massachusetts 02115|